0001357878
false
0001357878
2026-09-01
2026-09-01
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
xbrli:pure
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): September 1, 2026
REGENEREX PHARMA, INC
(Exact Name of Registrant as Specified in its Charter)
Nevada |
|
000-53230 |
|
98-0479983 |
(State or
Other Jurisdiction of
Incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer Identification No.) |
5348
Vegas Drive #177 Las
Vegas, NV |
|
89108 |
(Address of
Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone number, including area
code: (877) 761-7479
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
|
[ ] |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
[ ] |
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
[ ] |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
|
[ ] |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e 4(c)) |
Securities registered pursuant to Section
12(b) of the Act: None.
Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has
elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section
13(a) of the Exchange Act. [ ]
Item 8.01 Other Events
Status of Periodic Reports and Efforts to Become Current in SEC Filings
Regenerex Pharma,
Inc. (the “Company”) is filing this Current Report on Form 8-K to provide an
update to its shareholders and other interested parties regarding the status of
the Company’s periodic reporting obligations under the Securities Exchange Act
of 1934, as amended (the “Exchange Act”).
The Company recently
completed and filed its Annual Report on Form 10-K for the fiscal year ended December
31, 2025 (the “2025 Form 10-K”). The 2025 Form 10-K was filed after the
applicable filing deadline.
The Company is
currently working to complete and file its Quarterly Reports on Form 10-Q for
the quarters ended March 31, 2026 and June 30, 2026 (collectively, the
“Outstanding Quarterly Reports”). The Outstanding Quarterly Reports have not
yet been filed with the Securities and Exchange Commission (the “SEC”) and are
therefore delinquent.
The Company
acknowledges that it did not file Notifications of Late Filing on Form 12b-25
with respect to the Outstanding Quarterly Reports. The Company is making this
disclosure to provide transparency to its shareholders and the investment
community regarding the status of its SEC reporting obligations.
The delay in
completing the Outstanding Quarterly Reports has primarily resulted from the
substantial additional accounting, reconciliation, financial reporting, and
related review work required in connection with the completion and filing of
the Company's 2025 Form 10-K and the preparation of the Company's quarterly
financial statements and related disclosures. The Company has undertaken
additional procedures to review and reconcile its financial information and
supporting records in order to complete the Outstanding Quarterly Reports and
establish a reliable basis for its ongoing periodic reporting.
Management, together
with the Company's accounting and financial reporting personnel and other
professional advisors, is actively working to complete the Outstanding
Quarterly Reports and bring the Company current with its SEC periodic reporting
obligations as promptly as practicable.
The Company
recognizes the importance of timely, accurate, and complete financial reporting
to its shareholders and the investment community. Management is taking steps to
strengthen and improve the Company's financial reporting and filing processes
with the objective of maintaining timely compliance with its periodic reporting
obligations going forward.
The Company does not
currently anticipate that the delayed filing of the Outstanding Quarterly
Reports will result in any change to the Company's operations, business
strategy, or ongoing business activities. The Company continues to conduct its
business in the ordinary course and remains focused on its existing business
operations and objectives.
The Company will
continue to work diligently toward completion and filing of the Outstanding
Quarterly Reports and intends to file such reports as soon as practicable. The
Company will provide additional information through its SEC filings as
appropriate.
The Company cautions
shareholders and other interested parties that, until the Outstanding Quarterly
Reports are filed, the Company's financial information for the respective
quarterly periods should be considered incomplete and should be evaluated in
conjunction with the Company's other filings with the SEC.
Forward-Looking Statements
This Current Report
on Form 8-K contains certain statements that may constitute forward-looking
statements within the meaning of applicable federal securities laws, including
statements regarding the Company's efforts and expectations concerning the
timing of the completion and filing of its Outstanding Quarterly Reports, the
Company's financial reporting processes, and the Company's expectations
regarding its operations and business activities.
These
forward-looking statements are based upon the Company's current expectations,
plans, assumptions, and beliefs and are subject to risks and uncertainties that
could cause actual results or events to differ materially from those
anticipated or implied by such statements. Factors that could cause actual
results or events to differ include, among other things, the Company's ability
to complete its accounting and financial reporting processes, the completion of
required reviews, the availability and accuracy of financial information and
supporting documentation, and other matters that may arise in connection with
the preparation and filing of the Outstanding Quarterly Reports.
The Company
undertakes no obligation to update or revise any forward-looking statements,
except as may be required by applicable law.
Contact:
Regenerex Pharma, Inc.
Company
Ph: 877-761-RGPX (7479)
Investor
Relations Ph: (305) 927-5191
Email:
investors@regenerexpharmainc.com
regenerexpharma.com
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, hereunto duly authorized.
|
REGENEREX PHARMA,
INC. |
|
|
|
|
By: |
/s/ Greg Pilant |
Date: Sept 1, 2026 |
Name: |
Greg Pilant |
|
Title: |
Chief Executive Officer |
